Compare Adaptive Biotechnologies Corp (ADPT) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Target Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.22 (market cap $3.33B), while Target Corporation trades at $132.4 (market cap $57.93B). The key difference: Target Corporation is far larger — about 17.4× Adaptive Biotechnologies Corp's market cap, and Target Corporation pays a 3.64% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TGT | |
|---|---|---|
Market Cap | $3.33B | $57.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $141.19 |
52-Week Low | $10.24 | $83.68 |
Enterprise Value | $3.19B | $73.23B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Target trades at $127.55, down 2.04% today, with technical indicators showing bearish momentum. The stock maintains solid fundamentals with a P/E of 16.66 and net income margin of 3.24%, supported by three consecutive quarterly EPS beats. Recent news highlights Target's marketplace expansion and consumer resilience focus amid retail sector volatility.
The outlook remains balanced with a consensus price target of $137 offering 7.4% upside potential, though bearish technical signals and competitive pressures pose risks. Strong cash flow generation and dividend payments provide shareholder stability while execution on growth initiatives will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
